Ad is loading...
CMOPF
Price
$95.00
Change
-$0.00 (-0.00%)
Updated
Aug 27 closing price
DSNKY
Price
$29.59
Change
+$0.26 (+0.89%)
Updated
Nov 15 closing price
Ad is loading...

CMOPF vs DSNKY

Header iconCMOPF vs DSNKY Comparison
Open Charts CMOPF vs DSNKYBanner chart's image
Cosmo Pharmaceuticals
Price$95.00
Change-$0.00 (-0.00%)
Volume$213
CapitalizationN/A
Daiichi Sankyo
Price$29.59
Change+$0.26 (+0.89%)
Volume$249.63K
CapitalizationN/A
CMOPF vs DSNKY Comparison Chart
Loading...
DSNKY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CMOPF vs. DSNKY commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMOPF is a Hold and DSNKY is a Hold.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CMOPF: $95.00 vs. DSNKY: $29.59)
Brand notoriety: CMOPF and DSNKY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: CMOPF: 100% vs. DSNKY: 317%
Market capitalization -- CMOPF: $827.91M vs. DSNKY: $59.21B
CMOPF [@Pharmaceuticals: Major] is valued at $827.91M. DSNKY’s [@Pharmaceuticals: Major] market capitalization is $59.21B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMOPF’s FA Score shows that 1 FA rating(s) are green whileDSNKY’s FA Score has 0 green FA rating(s).

  • CMOPF’s FA Score: 1 green, 4 red.
  • DSNKY’s FA Score: 0 green, 5 red.
According to our system of comparison, CMOPF is a better buy in the long-term than DSNKY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DSNKY’s TA Score shows that 4 TA indicator(s) are bullish.

  • DSNKY’s TA Score: 4 bullish, 5 bearish.

Price Growth

CMOPF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while DSNKY (@Pharmaceuticals: Major) price change was -7.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.55%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was +2.00%.

Industries' Descriptions

@Pharmaceuticals: Major (-4.55% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DSNKY($59.2B) has a higher market cap than CMOPF($828M). DSNKY has higher P/E ratio than CMOPF: DSNKY (75.76) vs CMOPF (68.49). CMOPF YTD gains are higher at: 80.437 vs. DSNKY (8.832). DSNKY has higher annual earnings (EBITDA): 203B vs. CMOPF (42.1M). DSNKY has more cash in the bank: 825B vs. CMOPF (222M). CMOPF has less debt than DSNKY: CMOPF (176M) vs DSNKY (143B). DSNKY has higher revenues than CMOPF: DSNKY (1.28T) vs CMOPF (104M).
CMOPFDSNKYCMOPF / DSNKY
Capitalization828M59.2B1%
EBITDA42.1M203B0%
Gain YTD80.4378.832911%
P/E Ratio68.4975.7690%
Revenue104M1.28T0%
Total Cash222M825B0%
Total Debt176M143B0%
FUNDAMENTALS RATINGS
CMOPF vs DSNKY: Fundamental Ratings
CMOPF
DSNKY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
7856
SMR RATING
1..100
5760
PRICE GROWTH RATING
1..100
3963
P/E GROWTH RATING
1..100
10088
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMOPF's Valuation (22) in the null industry is significantly better than the same rating for DSNKY (88). This means that CMOPF’s stock grew significantly faster than DSNKY’s over the last 12 months.

DSNKY's Profit vs Risk Rating (56) in the null industry is in the same range as CMOPF (78). This means that DSNKY’s stock grew similarly to CMOPF’s over the last 12 months.

CMOPF's SMR Rating (57) in the null industry is in the same range as DSNKY (60). This means that CMOPF’s stock grew similarly to DSNKY’s over the last 12 months.

CMOPF's Price Growth Rating (39) in the null industry is in the same range as DSNKY (63). This means that CMOPF’s stock grew similarly to DSNKY’s over the last 12 months.

DSNKY's P/E Growth Rating (88) in the null industry is in the same range as CMOPF (100). This means that DSNKY’s stock grew similarly to CMOPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DSNKY
RSI
ODDS (%)
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
71%
MACD
ODDS (%)
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
69%
Advances
ODDS (%)
Bullish Trend 20 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
70%
View a ticker or compare two or three
Ad is loading...
DSNKY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIYX12.300.09
+0.74%
Nuveen Global Infrastructure I
GIRVX6.90-0.02
-0.29%
Goldman Sachs Intl Eq Div & Prem Inv
LVOAX20.82-0.25
-1.19%
Lord Abbett Value Opportunities A
HFMVX37.12-0.50
-1.33%
Hartford MidCap R6
TSGMX15.34-0.27
-1.73%
Transamerica Sustainable Growth Eq R6

CMOPF and

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
N/A
GSK - CMOPF
22%
Poorly correlated
-1.91%
NVS - CMOPF
21%
Poorly correlated
-0.33%
CHGCY - CMOPF
7%
Poorly correlated
-0.09%
DSNKY - CMOPF
5%
Poorly correlated
+0.87%
CSPCY - CMOPF
4%
Poorly correlated
-1.14%
More

DSNKY and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSNKY has been loosely correlated with CHGCY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DSNKY jumps, then CHGCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSNKY
1D Price
Change %
DSNKY100%
+0.87%
CHGCY - DSNKY
38%
Loosely correlated
-0.09%
OTSKY - DSNKY
37%
Loosely correlated
-1.08%
DSKYF - DSNKY
34%
Loosely correlated
+10.11%
BIIB - DSNKY
23%
Poorly correlated
-2.97%
ALPMY - DSNKY
21%
Poorly correlated
N/A
More